Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538002 | 0.87 | RXFP1 (0.45) | RXFP1PTGESMAPTTP53SMN1; SMN2 | |
| SCHEMBL8488361 | 0.86 | RXFP1 (0.47) | RXFP1PTGESMAPTTP53PTGS1 | |
| SCHEMBL6538197 | 0.85 | PTGES (0.43) | RXFP1PTGESMAPTTP53F2R | |
| SCHEMBL6537426 | 0.85 | PTGES (0.50) | RXFP1PTGESNR3C1 | |
| SCHEMBL8486940 | 0.82 | PTGES (0.45) | RXFP1PTGESMAPTTP53KCNK3 | |
| SCHEMBL6537770 | 0.79 | TYK2 (0.43) | MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL6537918 | 0.78 | PTGES (0.42) | RXFP1PTGESTP53NR3C1 | |
| SCHEMBL6538369 | 0.78 | PTGES (0.44) | RXFP1PTGESMAPTTP53SMN1; SMN2 | |
| SCHEMBL8486693 | 0.77 | GSK3A (0.41) | MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL8488768 | 0.77 | DYRK3 (0.41) | RXFP1PTGESMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876345-B1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | disclosed |